Back to products

Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer agents in preclinical trials

Anticancer molecular libraries

MedKoo product information:

Axitinib

Description of axitinib: axitinib is an orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

Current developer:    Pfizer.

Axitinib (also known as AG013736) is a small molecule tyrosine kinase inhibitor under development by Pfizer. It inhibits multiple targets, including VEGFR-1, VEGFR-2, VEGFR-3, platelet derived growth factor receptor (PDGFR), and cKIT (CD117). It has been shown to significantly inhibit growth of breast cancer in xenograft models  and has been successful in trials with renal cell carcinoma (RCC)  and several other tumor types.

A Phase II clinical trial showed good response in combination chemotherapy with Gemcitabine for advanced pancreatic cancer. However, Pfizer reported on January 30, 2009 that Phase III clinical trials of the drug when used in combination with Gemcitabine showed no evidence of improved survival rates over treatments using Gemcitabine alone for advanced pancreatic cancer and halted the trial.  see http://en.wikipedia.org/wiki/Axitinib.

 1: Lombardi G, Zustovich F, Donach M, Dalla Palma M, Nicoletto O, Pastorelli D. An update on targeted therapy in metastatic renal cell carcinoma. Urol Oncol. 2010 Apr 22. [Epub ahead of print] PubMed PMID: 20456985.

2: Scagliotti G, Govindan R. Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer. Oncologist. 2010;15(5):436-46. Epub 2010 Apr 28. PubMed PMID: 20427383.

3: Vickers MM, Choueiri TK, Rogers M, Percy A, Finch D, Zama I, Cheng T, North S, Knox JJ, Kollmannsberger C, McDermott DF, Rini BI, Heng DY. Clinical Outcome in Metastatic Renal Cell Carcinoma Patients After Failure of Initial Vascular Endothelial Growth Factor-Targeted Therapy. Urology. 2010 Mar 9. [Epub ahead of print] PubMed PMID: 20223508.

4: Ansari J, Glaholm J, McMenemin R, James ND, Hussain SA. Recent advances and future directions in the management of metastatic renal cell carcinoma. Anticancer Agents Med Chem. 2010 Mar;10(3):225-35. PubMed PMID: 20184547.

5: Mukohara T, Nakajima H, Mukai H, Nagai S, Itoh K, Umeyama Y, Hashimoto J, Minami H. Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: A phase I study in Japanese patients. Cancer Sci. 2009 Dec 9. [Epub ahead of print] PubMed PMID: 20180805.

6: Schmidinger M, Bellmunt J. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev. 2010 Feb 15. [Epub ahead of print] PubMed PMID: 20163917.

7: Keefe SM, Cohen MA, Brose MS. Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications. Clin Cancer Res. 2010 Feb 1;16(3):778-83. Epub 2010 Jan 26. Review. PubMed PMID: 20103668.

8: Suárez C, Morales R, Muñoz E, Rodón J, Valverde CM, Carles J. Molecular basis for the treatment of renal cell carcinoma. Clin Transl Oncol. 2010 Jan;12(1):15-21. Review. PubMed PMID: 20080466.

9: Kelly RJ, Rixe O. Axitinib (AG-013736). Recent Results Cancer Res. 2010;184:33-44. Review. PubMed PMID: 20072829.

10: Yogi A, O'Connor SE, Callera GE, Tostes RC, Touyz RM. Receptor and nonreceptor tyrosine kinases in vascular biology of hypertension. Curr Opin Nephrol Hypertens. 2010 Mar;19(2):169-76. Review. PubMed PMID: 20051848.

11: Kessler T, Bayer M, Schwöppe C, Liersch R, Mesters RM, Berdel WE. Compounds in clinical Phase III and beyond. Recent Results Cancer Res. 2010;180:137-63. Review. PubMed PMID: 20033382.

12: Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer. 2010 Jan;46(2):439-48. Epub 2009 Dec 16. Review. PubMed PMID: 20006922.

13: Ainsworth NL, Lee JS, Eisen T. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2009 Dec;9(12):1793-805. Review. PubMed PMID: 19954291.

14: Sherman SI. Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab. 2009 Dec;23(6):713-22. Review. PubMed PMID: 19942148.

15: Sharma S, Abhyankar V, Burgess RE, Infante J, Trowbridge RC, Tarazi J, Kim S, Tortorici M, Chen Y, Robles RL. A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. Ann Oncol. 2010 Feb;21(2):297-304. Epub 2009 Nov 25. PubMed PMID: 19940012.

16: Sparidans RW, Iusuf D, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Dec 15;877(32):4090-6. Epub 2009 Oct 30. PubMed PMID: 19910267.

17: Kelly RJ, Rixe O. Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. Target Oncol. 2009 Dec;4(4):297-305. Epub 2009 Oct 30. PubMed PMID: 19876699.

18: Facchini G, Perri F, Caraglia M, Pisano C, Striano S, Marra L, Fiore F, Aprea P, Pignata S, Iaffaioli RV. New treatment approaches in renal cell carcinoma. Anticancer Drugs. 2009 Nov;20(10):893-900. Review. PubMed PMID: 19752718.

19: Di Lorenzo G, Autorino R, Sternberg CN. Metastatic Renal Cell Carcinoma: Recent Advances in the Targeted Therapy Era. Eur Urol. 2009 Sep 8. [Epub ahead of print] PubMed PMID: 19748725.

20: Wasan HS, Springett GM, Chodkiewicz C, Wong R, Maurel J, Barone C, Rosbrook B, Ricart AD, Kim S, Spano JP. CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone. Br J Cancer. 2009 Oct 6;101(7):1162-7. Epub 2009 Sep 1. PubMed PMID: 19724276; PubMed Central PMCID: PMC2768104.

21: Cella D. Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes. Cancer Treat Rev. 2009 Dec;35(8):733-7. Epub 2009 Aug 21. Review. PubMed PMID: 19699588.

22: Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009 Sep 20;27(27):4462-8. Epub 2009 Aug 3. PubMed PMID: 19652060.

23: Sugawara M, Geffner DL, Martinez D, Hershman JM. Novel treatment of medullary thyroid cancer. Curr Opin Endocrinol Diabetes Obes. 2009 Oct;16(5):367-72. Review. PubMed PMID: 19633548.

24: Hersey P, Bastholt L, Chiarion-Sileni V, Cinat G, Dummer R, Eggermont AM, Espinosa E, Hauschild A, Quirt I, Robert C, Schadendorf D. Small molecules and targeted therapies in distant metastatic disease. Ann Oncol. 2009 Aug;20 Suppl 6:vi35-40. Review. PubMed PMID: 19617296; PubMed Central PMCID: PMC2712592.

25: Pithavala YK, Tortorici M, Toh M, Garrett M, Hee B, Kuruganti U, Ni G, Klamerus KJ. Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. Cancer Chemother Pharmacol. 2010 Feb;65(3):563-70. Epub 2009 Jul 15. PubMed PMID: 19603168; PubMed Central PMCID: PMC2797436.

26: Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ, von Pawel J. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol. 2009 Aug 10;27(23):3836-41. Epub 2009 Jul 13. PubMed PMID: 19597027.

27: Fenton BM, Paoni SF. Alterations in daily sequencing of axitinib and fractionated radiotherapy do not affect tumor growth inhibition or pathophysiological response. Radiat Res. 2009 May;171(5):606-14. PubMed PMID: 19580496; PubMed Central PMCID: PMC2707773.

28: Solowiej J, Bergqvist S, McTigue MA, Marrone T, Quenzer T, Cobbs M, Ryan K, Kania RS, Diehl W, Murray BW. Characterizing the effects of the juxtamembrane domain on vascular endothelial growth factor receptor-2 enzymatic activity, autophosphorylation, and inhibition by axitinib. Biochemistry. 2009 Jul 28;48(29):7019-31. PubMed PMID: 19526984.

29: O'Reilly EM. Pancreatic adenocarcinoma: new strategies for success. Gastrointest Cancer Res. 2009 Mar;3(2 Suppl):S11-5. PubMed PMID: 19461915; PubMed Central PMCID: PMC2684727.

30: Ito Y, Kobayashi K. [Chemotherapy for breast cancer refractory to anthracycline, taxane or trastuzumab]. Gan To Kagaku Ryoho. 2009 May;36(5):726-9. Japanese. PubMed PMID: 19461171.

31: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Mar;31(2):107-46. PubMed PMID: 19455266.

32: Rini BI. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. Cancer. 2009 May 15;115(10 Suppl):2306-12. Review. PubMed PMID: 19402073.

33: Atkins MB, Choueiri TK, Cho D, Regan M, Signoretti S. Treatment selection for patients with metastatic renal cell carcinoma. Cancer. 2009 May 15;115(10 Suppl):2327-33. Review. PubMed PMID: 19402069; PubMed Central PMCID: PMC2762357.

34: Sennino B, Kuhnert F, Tabruyn SP, Mancuso MR, Hu-Lowe DD, Kuo CJ, McDonald DM. Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors. Cancer Res. 2009 May 15;69(10):4527-36. Epub 2009 Apr 28. PubMed PMID: 19401451; PubMed Central PMCID: PMC2759816.

35: Launay-Vacher V, Deray G. Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs. 2009 Jan;20(1):81-2. PubMed PMID: 19343005.

36: Bastien L, Culine S, Paule B, Ledbai S, Patard JJ, de la Taille A. Targeted therapies in metastatic renal cancer in 2009. BJU Int. 2009 May;103(10):1334-42. Epub 2009 Mar 11. Review. PubMed PMID: 19338565.

37: Mizutani Y. Recent advances in molecular targeted therapy for metastatic renal cell carcinoma. Int J Urol. 2009 May;16(5):444-8. Epub 2009 Mar 3. Review. PubMed PMID: 19298634.

38: Tomillero A, Moral MA. Gateways to clinical trials. December 2008. Methods Find Exp Clin Pharmacol. 2008 Dec;30(10):761-82. PubMed PMID: 19271026.

39: Bukowski RM. Axitinib treatment in patients with cytokine-refractory metastatic renal cell cancer. Curr Oncol Rep. 2009 Mar;11(2):81-3. PubMed PMID: 19216838.

40: Malouf G, Baudin E, Soria JC, Schlumberger M. [Advances in the treatment of thyroid cancer in the era of molecularly targeted therapies]. Bull Cancer. 2009 Jan;96(1):95-101. Review. French. PubMed PMID: 19211364.

41: Ma J, Waxman DJ. Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib. Clin Cancer Res. 2009 Jan 15;15(2):578-88. PubMed PMID: 19147763; PubMed Central PMCID: PMC2729124.

42: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Oct;30(8):643-72. PubMed PMID: 19088949.

43: Heng DY, Bukowski RM. Anti-angiogenic targets in the treatment of advanced renal cell carcinoma. Curr Cancer Drug Targets. 2008 Dec;8(8):676-82. Review. PubMed PMID: 19075590.

44: Alexandre I, Billemont B, Meric JB, Richard S, Rixe O. Axitinib induces paradoxical erythropoietin synthesis in metastatic renal cell carcinoma. J Clin Oncol. 2009 Jan 20;27(3):472-3; author reply 473-4. Epub 2008 Dec 15. PubMed PMID: 19075253.

45: Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008 Nov 15;14(22):7272-83. PubMed PMID: 19010843.

46: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Sep;30(7):543-88. PubMed PMID: 18985183.

47: Tomillero A, Moral MA. Gateways to clinical trials. July-August 2008. Methods Find Exp Clin Pharmacol. 2008 Jul-Aug;30(6):459-95. PubMed PMID: 18850047.

48: Döme B, Magyar M. [Tumor vasculature as a therapeutic target in non-small cell lung cancer]. Magy Onkol. 2008 Sep;52(3):247-59. Review. Hungarian. PubMed PMID: 18845495.

49: Escudier B. Signaling inhibitors in metastatic renal cell carcinoma. Cancer J. 2008 Sep-Oct;14(5):325-9. PubMed PMID: 18836338.

50: Staehler M, Haseke N, Zilinberg K, Stadler T, Karl A, Stief CG. [Systemic therapy of metastasizing renal cell carcinoma]. Urologe A. 2008 Oct;47(10):1357-67. German. PubMed PMID: 18825295.

51: Vakkalanka BK, Bukowski RM. Novel drugs for renal cell carcinoma. Expert Opin Investig Drugs. 2008 Oct;17(10):1501-16. Review. PubMed PMID: 18808310.

52: Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, Golshayan AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol. 2008 Sep;180(3):860-5; discussion 865-6. Epub 2008 Jul 17. PubMed PMID: 18635227.

53: Trask PC, Bushmakin AG, Cappelleri JC, Bycott P, Liau K, Kim S. Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib. Acta Oncol. 2008;47(5):843-51. PubMed PMID: 18568482.

54: Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008 Oct 10;26(29):4708-13. Epub 2008 Jun 9. PubMed PMID: 18541897.

55: Choueiri TK. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Curr Opin Investig Drugs. 2008 Jun;9(6):658-71. Review. PubMed PMID: 18516765.

56: Spano JP, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C, Létourneau R, Bajetta E, Pithavala Y, Bycott P, Trask P, Liau K, Ricart AD, Kim S, Rixe O. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet. 2008 Jun 21;371(9630):2101-8. Epub 2008 May 29. PubMed PMID: 18514303.

57: Philip PA. Targeting angiogenesis in pancreatic cancer. Lancet. 2008 Jun 21;371(9630):2062-4. Epub 2008 May 29. PubMed PMID: 18514302.

58: Sherman SI. Early clinical studies of novel therapies for thyroid cancers. Endocrinol Metab Clin North Am. 2008 Jun;37(2):511-24, xi. Review. PubMed PMID: 18502340.

59: Sonpavde G, Hutson TE, Rini BI. Axitinib for renal cell carcinoma. Expert Opin Investig Drugs. 2008 May;17(5):741-8. Review. Erratum in: Expert Opin Investig Drugs. 2008 Sep;17(9):1405. PubMed PMID: 18447599.

60: Bayés M, Rabasseda X. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Jan-Feb;30(1):67-99. PubMed PMID: 18389098.

61: Ma J, Waxman DJ. Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol Cancer Ther. 2008 Jan;7(1):79-89. PubMed PMID: 18202011; PubMed Central PMCID: PMC2390754.

62: Deshpande HA, Gettinger SN, Sosa JA. Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope. Curr Opin Oncol. 2008 Jan;20(1):19-24. Review. PubMed PMID: 18043252.

63: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Sep;29(7):467-509. PubMed PMID: 17982511.

64: Meric JB. [Angiogenesis targeting in gastro-intestinal cancers]. Bull Cancer. 2007;94(7 Suppl):F207-15. Review. French. PubMed PMID: 17964998.

65: Linehan WM. Targeting VEGF receptors in kidney cancer. Lancet Oncol. 2007 Nov;8(11):956-7. PubMed PMID: 17976606.

66: Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol. 2007 Nov;8(11):975-84. Epub 2007 Oct 23. PubMed PMID: 17959415.

67: Fenton BM, Paoni SF. The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature. Cancer Res. 2007 Oct 15;67(20):9921-8. PubMed PMID: 17942924.

68: Hutson TE, Figlin RA. Evolving role of novel targeted agents in renal cell carcinoma. Oncology (Williston Park). 2007 Sep;21(10):1175-80; discussion 1184, 1187, 1190. Review. PubMed PMID: 17926797.

69: Billemont B, Méric JB, Izzedine H, Taillade L, Sultan-Amar V, Rixe O. [Angiogenesis and renal cell carcinoma]. Bull Cancer. 2007 Jul;94 Spec No:S232-40. Review. French. PubMed PMID: 17846009.

70: Ropert S, Mir O, Armand JP. [Oral drugs inhibiting the VEGF pathway]. Bull Cancer. 2007 Jul;94 Spec No:S180-90. Review. French. PubMed PMID: 17846003.

71: Kibble A. American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3. IDrugs. 2007 Aug;10(8):520-2. PubMed PMID: 17665322.

72: Larkin JM, Chowdhury S, Gore ME. Drug insight: advances in renal cell carcinoma and the role of targeted therapies. Nat Clin Pract Oncol. 2007 Aug;4(8):470-9. Review. PubMed PMID: 17657252.

73: Hutson TE. Targeted therapy for renal cell carcinoma: a new treatment paradigm. Proc (Bayl Univ Med Cent). 2007 Jul;20(3):244-8. PubMed PMID: 17637878; PubMed Central PMCID: PMC1906573.

74: Cabebe E, Wakelee H. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol. 2007 Feb;8(1):15-27. Review. PubMed PMID: 17634832.

75: Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR, Baz RC, Wood L, Rini BI, Bukowski RM. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007 Aug 1;110(3):543-50. PubMed PMID: 17577222.

76: Sartore-Bianchi A, Ricotta R, Cerea G, Maugeri MR, Siena S. Rationale and clinical results of multi-target treatments in oncology. Int J Biol Markers. 2007 Jan-Mar;22(1 Suppl 4):S77-87. Review. PubMed PMID: 17520585.

77: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Apr;29(3):231-45. PubMed PMID: 17520107.

78: Bayes M. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Mar;29(2):153-73. PubMed PMID: 17440629.

79: Wilmes LJ, Pallavicini MG, Fleming LM, Gibbs J, Wang D, Li KL, Partridge SC, Henry RG, Shalinsky DR, Hu-Lowe D, Park JW, McShane TM, Lu Y, Brasch RC, Hylton NM. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging. 2007 Apr;25(3):319-27. Epub 2007 Feb 5. PubMed PMID: 17371720.

80: George DJ. Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):753s-757s. Review. PubMed PMID: 17255305.

81: Hutson TE, Sonpavde G, Galsky MD. Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials. Clin Genitourin Cancer. 2006 Dec;5 Suppl 1:S31-9. Review. PubMed PMID: 17239282.

82: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Dec;28(10):719-40. PubMed PMID: 17235418.

83: Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, Shalinsky DR, Hu-Lowe DD, McDonald DM. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 2006 Oct;116(10):2610-21. PubMed PMID: 17016557; PubMed Central PMCID: PMC1578604.

84: Mancuso A, Sternberg CN. New treatment approaches in metastatic renal cell carcinoma. Curr Opin Urol. 2006 Sep;16(5):337-41. Review. PubMed PMID: 16905978.

85: Larkin JM, Eisen T. Kinase inhibitors in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol. 2006 Dec;60(3):216-26. Epub 2006 Jul 24. Review. PubMed PMID: 16860997.

86: Eto M, Naito S. Molecular targeting therapy for renal cell carcinoma. Int J Clin Oncol. 2006 Jun;11(3):209-13. Review. PubMed PMID: 16850127.

87: Rini BI, Jaeger E, Weinberg V, Sein N, Chew K, Fong K, Simko J, Small EJ, Waldman FM. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int. 2006 Oct;98(4):756-62. Epub 2006 Jul 7. PubMed PMID: 16827904.

88: Guo J, Marcotte PA, McCall JO, Dai Y, Pease LJ, Michaelides MR, Davidsen SK, Glaser KB. Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther. 2006 Apr;5(4):1007-13. PubMed PMID: 16648572.

89: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Mar;28(2):121-42. PubMed PMID: 16636723.

90: Yao VJ, Ozawa MG, Varner AS, Kasman IM, Chanthery YH, Pasqualini R, Arap W, McDonald DM. Antiangiogenic therapy decreases integrin expression in normalized tumor blood vessels. Cancer Res. 2006 Mar 1;66(5):2639-49. PubMed PMID: 16510583.

91: Rini BI. VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices. Curr Oncol Rep. 2006 Mar;8(2):85-9. Review. PubMed PMID: 16507216.

92: Koga S, Kanetake H. [Progress in therapeutic strategy for renal cell carcinoma]. Gan To Kagaku Ryoho. 2006 Feb;33(2):171-7. Review. Japanese. PubMed PMID: 16484851.

93: Nakahara T, Norberg SM, Shalinsky DR, Hu-Lowe DD, McDonald DM. Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res. 2006 Feb 1;66(3):1434-45. PubMed PMID: 16452199.

94: Gollob JA. Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma. Clin Genitourin Cancer. 2005 Dec;4(3):167-74. Review. PubMed PMID: 16425993.

95: Rini BI. SU11248 and AG013736: current data and future trials in renal cell carcinoma. Clin Genitourin Cancer. 2005 Dec;4(3):175-80. Review. PubMed PMID: 16425985.

96: Giles FJ, Bellamy WT, Estrov Z, O'Brien SM, Verstovsek S, Ravandi F, Beran M, Bycott P, Pithavala Y, Steinfeldt H, Reich SD, List AF, Yee KW. The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leuk Res. 2006 Jul;30(7):801-11. Epub 2005 Dec 5. PubMed PMID: 16332390.

97: Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, Norberg SM, O'Brien SM, Davis RB, Gowen LC, Anderson KD, Thurston G, Joho S, Springer ML, Kuo CJ, McDonald DM. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H560-76. Epub 2005 Sep 19. PubMed PMID: 16172168.

98: Baffert F, Le T, Sennino B, Thurston G, Kuo CJ, Hu-Lowe D, McDonald DM. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H547-59. Epub 2005 Sep 19. PubMed PMID: 16172161.

99: Li KL, Wilmes LJ, Henry RG, Pallavicini MG, Park JW, Hu-Lowe DD, McShane TM, Shalinsky DR, Fu YJ, Brasch RC, Hylton NM. Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI. J Magn Reson Imaging. 2005 Oct;22(4):511-9. PubMed PMID: 16161072.

100: Wakelee HA, Schiller JH. Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer. Clin Lung Cancer. 2005 Sep;7 Suppl 1:S31-8. Review. PubMed PMID: 16159417.

101: Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol. 2005 Aug 20;23(24):5474-83. Epub 2005 Jul 18. PubMed PMID: 16027439.

102: Collins JM. Imaging and other biomarkers in early clinical studies: one step at a time or re-engineering drug development? J Clin Oncol. 2005 Aug 20;23(24):5417-9. Epub 2005 Jul 18. PubMed PMID: 16027435.

103: Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, Thurston G, Yancopoulos GD, McDonald DM. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004 Jul;165(1):35-52. PubMed PMID: 15215160; PubMed Central PMCID: PMC1618540.

104: Derry WB, Putzke AP, Rothman JH. Caenorhabditis elegans p53: role in apoptosis, meiosis, and stress resistance. Science. 2001 Oct 19;294(5542):591-5. Epub 2001 Sep 13. PubMed PMID: 11557844.

105: Sugimoto A, Kusano A, Hozak RR, Derry WB, Zhu J, Rothman JH. Many genomic regions are required for normal embryonic programmed cell death in Caenorhabditis elegans. Genetics. 2001 May;158(1):237-52. PubMed PMID: 11333233; PubMed Central PMCID: PMC1461632.

106: Ferguson KC, Rothman JH. Alterations in the conserved SL1 trans-spliced leader of Caenorhabditis elegans demonstrate flexibility in length and sequence requirements in vivo. Mol Cell Biol. 1999 Mar;19(3):1892-900. PubMed PMID: 10022876; PubMed Central PMCID: PMC83982.